- Video Center
- Social Media
- Media Contacts
Leverkusen, May 13, 2022 – Bayer AG today celebrated the topping-out ceremony of its new pharmaceutical facility in Leverkusen in the presence of German Federal Chancellor Olaf Scholz, German Minister of Health Professor Dr. Karl Lauterbach and many other guests from the worlds of politics and business. Scholz met with Chairman of the Board of Management of Bayer AG Werner Baumann, Chairman of the Supervisory Board Professor Dr. Norbert Winkeljohann and Chairwoman of the Central Works Council Heike Hausfeld before the ceremony to discuss Bayer’s concept for the company’s future in Germany and other current topics. “The investment in the new production plant demonstrates great confidence in the region as a center of the chemical and pharmaceutical industry. Projects like this are crucial to ensuring that Germany remains one of the global leaders economically and technologically in the 21st century,” said Olaf Scholz during his visit to Leverkusen. “Bayer is clearly committed to Germany as a base of operations, both now and in the future,” declared Baumann. “Our new pharmaceutical production plant at our site in Leverkusen is a shining example of precisely that. It will set completely new standards in digitalization and energy efficiency.”
The new Solida-1 production facility will be one of the most modern pharmaceutical production plants in the world. It is part of a billion-euro investment program that Bayer AG is implementing to strengthen its pharmaceutical production network and the company’s in-house innovation power. “The construction of the new Solida-1 production plant will help us ensure that the results of scientific research are transformed into products as quickly as possible, thereby making a lasting improvement to patients’ lives,” said Baumann. The facility will be used to manufacture medicinal products for the treatment of cancer and cardiovascular diseases, for example.
The state-of-the-art plant will be at the heart of the new global Center of Excellence for the production of solid pharmaceutical products at the Leverkusen site. It will not only set standards for efficiency, quality, supply security and sustainability, but will also leverage the advantages of digitalization in a “learning factory” – an environment in which data streams are analyzed using artificial intelligence in order to derive action recommendations.
The construction of the new production facility is both part of Bayer’s Pharmaceuticals strategy and an item on the company’s sustainability agenda. One important element here is the production focus on support for major future growth areas where Bayer is working to improve the therapeutic options available to patients.
However, the facility also sets new standards in regard to sustainability. Its energy requirements are largely covered by a cutting-edge geothermal plant which reduces CO2 emissions by 70 percent compared to conventional systems. The modular construction of Solida-1 facilitates extensions to the facility, thus ensuring maximum flexibility to react to future developments in the pharmaceuticals industry.
The single-story facility with a total floor area of approximately 15,000 m2 is scheduled to be ready for operation in 2024. Some 100 employees will then work in the building. The total investment by Bayer amounts to approximately 275 million euros.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
Follow us on Twitter twitter.com/BayerDialog
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center